HKEX Announcement Highlights | GUOXIA TECH to List Tomorrow with 1,890.73x Oversubscription; Big Three Airlines Report Over 10% YoY Passenger Traffic Growth in November

Stock News
Yesterday

【New Listings】 GUOXIA TECH (02655): Hong Kong public offering oversubscribed by 1,890.73 times, with an issue price of HK$20.1 per share. EasyHealth (02661) opens subscription from Dec 15 to Dec 18, expected to list on Dec 23. Hanshi Aite-B (03378) opens subscription from Dec 15 to Dec 18, expected to list on Dec 23. Nobikan (02635) opens subscription from Dec 15 to Dec 18, expected to list on Dec 23.

【Major Developments】 CMOC (03993) plans to acquire three major gold mining assets in Brazil for US$1.015 billion. CNGR (02579) H-shares included in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect lists. Botai Auto (02889) secures first project nomination from a leading domestic NEV customer. Concornew Energy (00182) to sell 100% equity in Cangzhou Julong for RMB65.3 million. FOSUN PHARMA (02196) subsidiary to invest RMB1.412 billion for a controlling stake in Green Valley Pharma. UQ Holdings (02177) to acquire Japanese pharmacy chain Akahige for JPY2.701 billion.

【Financial Data】 MCC (01618) reports new contract value of RMB958.13 billion for Jan-Nov, down 8.6% YoY. New China Life (01336) records RMB188.85 billion in premium income for Jan-Nov, up 16% YoY. China Southern Airlines (01055) sees November passenger traffic rise 10.42% YoY. China Shenhua (01088) coal sales volume at 389.5 million tonnes for Jan-Nov, down 7.7% YoY. China Eastern Airlines (00670) reports 10.35% YoY growth in November passenger traffic. Air China (00753) passenger traffic up 10.1% YoY in November.

【Buybacks & Share Purchases】 TENCENT (00700) repurchases 1.051 million shares for HK$636 million on Dec 15. Xiaomi (01810) buys back 7.2 million shares for HK$302 million on Dec 15. Geely Auto (00175) repurchases 1.991 million shares for HK$34.75 million on Dec 15. Kuaishou-W (01024) acquires 462,000 shares for HK$29.93 million on Dec 15. RemeGen (09995) plans buyback worth RMB20-40 million. Everest Medicines (01952) receives over HK$38 million in share purchases from directors and major shareholders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10